Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.
Blood Cancer J · 2025-Oct-06 · PMID 41053004
PFS
Fig. 2. Subgroup analysis of PFS by cytogenetic risk. A PFS by cytogenetic risk per original criteria. High-risk cytogenetics per the original definition are defined as ≥1 abnormality including del(17p), t(4;14), and/or t(14;16). B PFS by cytogenetic risk per revised criteria. Revised high-risk cytogenetics per the revised definition are defined as ≥1 abnormality including del(17p), t(4;14), t(14;16), t(14;20), and/or gain/amp(1q21). C PFS by cytogenetic risk per modified IMS 2024 criteria. High risk per the modified IMS 2024 criteria is defined as the presence of ≥20% del(17p); del(1p32) co-occurring with gain/amp(1q21); or t(4;14), t(14;16), and/or t(14;20) co-occurring with gain/amp(1q21) and/or del(1p32). In the AURIGA study, data were not available on TP53 mutations, beta-2-microglobulin and creatinine levels at the time of multiple myeloma diagnosis, and differentiation between monoallelic versus biallelic del(1p32). D PFS by the number of HRCAs, defined as the number of abnormalities from del(17p), t(4;14), t(14;16), t(14;20), and/or gain/amp(1q21). Cytogenetic results at diagnosis (based on clinical report form collected data from local labs) were used in the analysis. PFS, progression-free survival; IMS, International Myeloma Society; HRCA, high-risk cytogenetic abnormality; D-R, daratumumab/lenalidomide; R, lenalidomide; HR, hazard ratio; CI, confidence interval. a HR and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable. An HR <1 indicates an advantage for D-R maintenance.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 0.9775 | 40.0000 | 106 | 2 | |
| 1 | 2 | 0.7723 | 0.9775 | 40.0000 | 279 | 2 | |
| 1 | 3 | 0.7768 | 0.9775 | 40.0000 | 280 | 2 | |
| 1 | 4 | 0.7812 | 0.9775 | 40.0000 | 281 | 2 | |
| 1 | 5 | 0.7857 | 0.9775 | 40.0000 | 282 | 2 | |
| 1 | 6 | 0.7902 | 0.9775 | 40.0000 | 283 | 2 | |
| 1 | 7 | 0.7946 | 0.9775 | 40.0000 | 284 | 2 | |
| 1 | 8 | 0.7991 | 0.9775 | 40.0000 | 285 | 2 | |
| 1 | 9 | 0.8036 | 0.9775 | 40.0000 | 286 | 2 | |
| 1 | 10 | 0.8080 | 0.9775 | 40.0000 | 287 | 2 | |
| 1 | 11 | 0.8125 | 0.9775 | 40.0000 | 288 | 2 | |
| 1 | 12 | 0.8170 | 0.9775 | 40.0000 | 289 | 2 | |
| 1 | 13 | 0.8214 | 0.9775 | 40.0000 | 290 | 2 | |
| 1 | 14 | 0.8259 | 0.9775 | 40.0000 | 291 | 2 | |
| 1 | 15 | 0.9018 | 0.9775 | 40.0000 | 308 | 2 | |
| 1 | 16 | 0.9062 | 0.9775 | 40.0000 | 309 | 2 | |
| 1 | 17 | 0.9107 | 0.9775 | 40.0000 | 310 | 2 | |
| 1 | 18 | 0.9152 | 0.9775 | 40.0000 | 311 | 2 | |
| 1 | 19 | 0.9196 | 0.9775 | 40.0000 | 312 | 2 | |
| 1 | 20 | 0.9241 | 0.9775 | 40.0000 | 313 | 2 | |
| 1 | 21 | 0.9286 | 0.9775 | 40.0000 | 314 | 2 | |
| 1 | 22 | 0.9330 | 0.9775 | 40.0000 | 315 | 2 | |
| 1 | 23 | 0.9375 | 0.9775 | 40.0000 | 316 | 2 | |
| 1 | 24 | 0.9420 | 0.9775 | 40.0000 | 317 | 2 | |
| 1 | 25 | 0.9464 | 0.9775 | 40.0000 | 318 | 2 | |
| 1 | 26 | 0.9509 | 0.9775 | 40.0000 | 319 | 2 | |
| 1 | 27 | 0.9554 | 0.9775 | 40.0000 | 320 | 2 | |
| 1 | 28 | 0.9598 | 0.9775 | 40.0000 | 321 | 2 | |
| 1 | 29 | 0.9643 | 0.9775 | 40.0000 | 322 | 2 | |
| 1 | 30 | 0.9688 | 0.9775 | 40.0000 | 323 | 2 | |
| 1 | 31 | 0.9732 | 0.9775 | 40.0000 | 324 | 2 | |
| 1 | 32 | 0.9777 | 0.9775 | 40.0000 | 325 | 2 | |
| 1 | 33 | 0.9821 | 0.9775 | 40.0000 | 326 | 2 | |
| 1 | 34 | 0.9866 | 0.9775 | 40.0000 | 327 | 2 | |
| 1 | 35 | 0.9911 | 0.9775 | 40.0000 | 328 | 2 | |
| 1 | 36 | 0.9955 | 0.9775 | 40.0000 | 329 | 2 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T18:00:52+00:00 |